|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes显示文摘Postprandial glucose level is an independent risk factor for cardiovascular disease that exerts effects greater than glucose levels at fasting state, whereas increase in serum triglyceride level, under both fasting and postprandial conditions, contributes to the development of arteriosclerosis. Insulin resistance is a prevailing cause of abnormalities in postabsorptive excursion of blood glucose and postprandial lipid profile. Excess fat deposition renders a vicious cycle of hyperglycemia and hypertriglyceridemia in the postprandial state, and both of which are contributors to atherosclerotic change of vessels especially in patients with type 2 diabetes mellitus. Several therapeutic approaches for ameliorating each of these abnormalities have been attempted, including various antidiabetic agents or new compounds targeting lipid metabolism. | Toru Hiyoshi Mutsunori Fujiwara Zemin Yao | 2019 | The Journal of Biomedical Research2019，33，1： | 5 |
| 2 | Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study显示文摘AIM: To assess the effects of sitagliptin and nateglinide on lipid metabolism. METHODS: In a parallel group comparative open trial, patients with type 2 diabetes mellitus under treatment at the Japanese Red Cross Medical Center were randomly assigned to receive either sitagliptin (50 mg once daily) or nateglinide (90 mg three times daily before meals). Eligible patients met the following criteria: age ≥ 20 years; hemoglobin A 1c (HbA 1c ) > 6.5% despite diet and exercise; HbA 1c between 6.5% and 8.0%; fasting glucose < 7.77 mmol/L; diet and exercise therapy for more than 3 mo; and ability to read and understand the information for written informed consent. Exclusion criteria were contraindications to sitagliptin, contraindications to nateglinide, pregnancy or possible pregnancy, and severe liver/renal failure. Patients who were considered to be unsuitable by the attending physician for other reasons were also excluded. Blood samples were collected at one and three hours after intake of a test meal. The primary outcome measure was the area under the curve (AUC) of apolipoprotein (Apo) B48 at three hours postprandially. RESULTS: Twenty patients were randomly assigned to the sitagliptin group and sixteen patients were randomized to the nateglinide group. All 36 patients took the medication as directed by the physician in both groups, and they all were analyzed. Apart from antidiabetic drugs, there was no difference between the two groups with respect to the frequency of combined use of lipid-lowering, antihypertensive, and/or antiplatelet drugs. The doses of these medications were maintained during 12 wk of treatment. Detailed dietary advice, together with adequate exercise therapy, was given to the patients so that other factors apart from the two test drugs were similar in the two groups. There were no significant differences of the baseline characteristics between the two groups, except for body mass index (the sitagliptin group: 25.14 ± 3.05 kg/m 2 ; the nateglinide group: 21.39 ± 2.24 kg/m 2 ). Fasting levels of HbA 1c , glycated albumin, 1.5-anhydroglucitol, and blood glucose, as well as the blood glucose levels at one and three hours postprandially, improved in both groups after 12 wk of treatment, and there were no significant differences between the two groups. However, the glucagon level at one hour postprandially (P = 0.040) and the diastolic blood pressure (P<0.01) only showed a significant decrease in the sitagliptin group. In the nateglinide group, there was no significant change in the AUC of Apo B48, the glucagon level at one hour postprandially, the fasting triglyceride level, or the diastolic blood pressure. Body weight was unchanged in both groups. However, the AUC of Apo B48 at three hours postprandially showed a significant decrease in the sitagliptin group from 2.48 ± 0.11 at baseline to 1.94 ± 0.78 g/L per hour after 12 wk (P=0.019). The fasting triglyceride level also decreased significantly in the sitagliptin group (P = 0.035). With regard to lipid-related markers other than Apo B48 and fasting triglycerides, no significant changes were observed with respect to Apo A1, Apo B, or Apo C3 in either group. No adverse events occurred in either group. CONCLUSION: Sitagliptin significantly improves some lipid parameters while having a comparable effect on blood glucose to nateglinide. A large-scale prospective study of sitagliptin therapy is warranted. | Yuichi Kojima Hideyoshi Kaga Shinu Hayashi Toru Kitazawa Yuko Iimura Makoto Ohno Michiyasu Yoshitsugu Mutsunori Fujiwara Toru Hiyoshi | 2013 | World Journal of Diabetes2013，4，1： | 5 |
| 3 | Characteristics of IFITM,the newly identified IFN-inducible anti-HIV-1 family proteins显示文摘 | Chutiwitoonchai N Hiyoshi M Hiyoshi-Yoshidomi Y | 2013 | Microbes Infect2013，15，： | 1 |
| 4 | Two regulators of Vibrio parahaemolyticus play important roles in enterotoxicity by controlling the expression of genes in the Vp-PAI region显示文摘 | Kodama T Gotoh K Hiyoshi H | 2010 | PLoS One2010，5，1： | 1 |
| 5 | MicroRNA-200b Regulates Cell Proliferation, Invasion, and Migration by Directly Targeting ZEB2 in Gastric Carcinoma显示文摘 | Junji Kurashige Hidenobu Kamohara Masayuki Watanabe Yukiharu Hiyoshi Masaaki Iwatsuki Youhei Tanaka Koichi Kinoshita Seiya Saito Yoshifumi Baba Hideo Baba | 2012 | Annals of Surgical Oncology2012，，3： | 1 |
| 6 | MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcino- ma显示文摘 | Hiyoshi Y Kamohara H Karashinaa R el al | 2009 | Clin Cancer Res2009，15，6： | 1 |
| 7 | MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cellcarcinoma显示文摘 | Hiyoshi Y Kamohara H Karashima R | 2009 | ClinCancer Res2009，15，6： | 1 |
| 8 | Two generalizations of an interpolant based Voronoi diagrams 显示文摘 | Hisamoto Hiyoshi Kokichi Sugihara | 1999 | International Journal of Shape Modeling1999，5，2： | 1 |
| 9 | Long-term results of treatment for pancreaticobiliary maljunction without bile duct dilatation显示文摘 | Ohuchida J Chijiiwa K Hiyoshi M | 2006 | Arch Surg2006，141，11： | 1 |
| 10 | Assay of DNA denaturation by polymerase chain reaction-driven fluorescent label Anal显示文摘 | Hiyoshi M Hosoi S | 1994 | Biochem1994，221，： | 1 |
| 11 | Study on interpolation based on Voronoi diagrams显示文摘 | Hisamoto Hiyoshi | 2000 | Tokyo: University of Tokyo2000，，： | 1 |
| 12 | d-Dopachrome tautomerase is a candidate for key protein to protect the rat liver damaged by carbon Tetrachloride显示文摘 | Hiyoshi M Konishi H Uemura H | 2009 | Toxicology2009，255，12： | 1 |
| 13 | Intrapancreatic accessory spleen mimicking endocrine tumor of the pancreas: case report and review of the literature显示文摘 | Uchiyama S Chijiiwa K Hiyoshi M | 2008 | J Gastrointest Surg2008，12，： | 1 |
| 14 | Long-term results of treatment of pancreaticobiliary maljunction without bile duct dilatation显示文摘 | Ohuchida J Chijiiwa K Hiyoshi M Kobayashi K Konomi H Tanaka M | 2006 | Arch Surg2006，141，： | 1 |
| 15 | Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding显示文摘 | Hiyoshi H Yayama K Takano M | 2004 | Hypertension2004，43，6： | 1 |
| 16 | The effects of microbial materials adhered to Asian sand dust on allergic lung inflammation 显示文摘 | ICHINOSE T YOSHIDA S HIYOSHI K | 2008 | Arch Environ Contain Toxicol2008，55，3： | 1 |
| 17 | MicroRNA-21 regu- lates the proliferation and invasion in esophageal squamous cell car- cinoma 显示文摘 | Hiyoshi Y Kamohara H Karashima R | 2009 | Clin Cancer Res2009，15，6： | 1 |
| 18 | mieroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma显示文摘 | Hiyoshi Y Kamohara H Kamshima R | 2009 | Clin Cancer Res2009，15，6： | 1 |
| 19 | Characteristics of IFITM,the newly identified IFN-inducible antiHIV-1 family proteins显示文摘 | Chutiwitoonchai N Hiyoshi M Hiyoshi-Yoshidomi Y | 2013 | Microbes Infect2013，，15： | 1 |
| 20 | Adsorption characteristics of carbon dioxide on organically functionalized SBA-15 显示文摘 | Hiyoshi N Yogo K Yashima T | 2005 | Microporous and Mesoporous Materials2005，84，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员